Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007

• Autores: Beltrán Gárate, Brady, Paredes Arcos, Antonio, Moisés Alfaro, Celia, Sanchez Félix, Gadwin, Riva Gonzales, Luis, Hurtado de Mendoza, Fernando, Cotrina Montenegro, Esther, Salas Rojas, Renzo
• Formato: artículo
• Fecha de Publicación: 2018
• Institución: Colegio Médico del Perú
• Repositorio: Acta Médica Peruana
• Lenguaje: español
• OAI Identifier: oai:amp.cmp.org.pe:article/2643
• Enlace del recurso: https://amp.cmp.org.pe/index.php/AMP/article/view/2643
• Nivel de acceso: acceso abierto
• Materia: linfoma cutáneo de células T; bexaroteno; interferon alfa; Cutaneous T-cell lymphoma; bexarotene; alpha-interferon

Introduction: Bexarotene is a rexinoid compound that is approved for use in the therapy for early and advanced stage cutaneous T-cell lymphoma (CTCL).Clinical Cases: We present in this report the results of the use of low-dose bexarotene plus phototherapy or alpha-interferon, nine million units, in the treatment of CTCL. Eight patients were treated, five had mycosis fungoides, two had CD-8 epidermothropic aggressive lymphoma. The overall response rate was 62.5% (5/8), and the mean duration of response was 20 months. Low-dose bexarotene combined with phototherapy or alpha-interferon may be effective in the treatment of CTCL.